ABSTRACT
Skin diseases bring great psychological and physical impacts on patients, however, a considerable number of skin diseases still lack effective treatments, such as psoriasis, systemic lupus erythematosus, melanoma and so on. Receptor-interacting serine threonine kinase 1 (RIPK1) plays an important role in cell death, especially necroptosis, associated with inflammation and tumor. As many molecules modulate the ubiquitination of RIPK1, disruption of this checkpoint can lead to skin diseases, which can be ameliorated by RIPK1 inhibitors. This review will focus on the molecular mechanism of RIPK1 activation in inflammation as well as the current knowledges on the contribution of RIPK1 in skin diseases.
Subject(s)
Dermatitis/immunology , Necroptosis/immunology , Protein Kinase Inhibitors/therapeutic use , Receptor-Interacting Protein Serine-Threonine Kinases/metabolism , Skin Neoplasms/immunology , Animals , Clinical Trials, Phase II as Topic , Dermatitis/drug therapy , Dermatitis/genetics , Dermatitis/pathology , Disease Models, Animal , Drug Evaluation, Preclinical , Half-Life , Humans , Imidazoles/pharmacology , Indoles/pharmacology , Mice , Mice, Knockout , Necroptosis/drug effects , Necroptosis/genetics , Oxazepines/pharmacology , Oxazepines/therapeutic use , Protein Kinase Inhibitors/pharmacology , Rats , Receptor-Interacting Protein Serine-Threonine Kinases/antagonists & inhibitors , Receptor-Interacting Protein Serine-Threonine Kinases/genetics , Signal Transduction/drug effects , Signal Transduction/genetics , Signal Transduction/immunology , Skin/drug effects , Skin/immunology , Skin/pathology , Skin Neoplasms/drug therapy , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Treatment Outcome , Triazoles/pharmacology , Triazoles/therapeutic use , Tumor-Associated Macrophages/drug effects , Tumor-Associated Macrophages/immunology , Tumor-Associated Macrophages/metabolism , Ubiquitination/immunologyABSTRACT
Trichuris trichiura is a human parasitic whipworm infecting around 500 million people globally, damaging the physical growth and educational performance of those infected. Current drug treatment options are limited and lack efficacy against the worm, preventing an eradication programme. It is therefore important to develop new treatments for trichuriasis. Using Trichuris muris, an established model for T. trichiura, we screened a library of 480 novel drug-like small molecules for compounds causing paralysis of the ex vivo adult parasite. We identified a class of dihydrobenz[e][1,4]oxazepin-2(3H)-one compounds with anthelmintic activity against T. muris. Further screening of structurally related compounds and resynthesis of the most potent molecules led to the identification of 20 active dihydrobenzoxazepinones, a class of molecule not previously implicated in nematode control. The most active immobilise adult T. muris with EC50 values around 25-50µM, comparable to the existing anthelmintic levamisole. The best compounds from this chemotype show low cytotoxicity against murine gut epithelial cells, demonstrating selectivity for the parasite. Developing a novel oral pharmaceutical treatment for a neglected disease and deploying it via mass drug administration is challenging. Interestingly, the dihydrobenzoxazepinone OX02983 reduces the ability of embryonated T. muris eggs to establish infection in the mouse host in vivo. Complementing the potential development of dihydrobenzoxazepinones as an oral anthelmintic, this supports an alternative strategy of developing a therapeutic that acts in the environment, perhaps via a spray, to interrupt the parasite lifecycle. Together these results show that the dihydrobenzoxazepinones are a new class of anthelmintic, active against both egg and adult stages of Trichuris parasites. They demonstrate encouraging selectivity for the parasite, and importantly show considerable scope for further optimisation to improve potency and pharmacokinetic properties with the aim of developing a clinical agent.
Subject(s)
Anthelmintics/pharmacology , Locomotion/drug effects , Oxazepines/pharmacology , Trichuris/drug effects , Trichuris/physiology , Animals , Anthelmintics/chemistry , Anthelmintics/toxicity , Cell Survival/drug effects , Disease Models, Animal , Drug Evaluation, Preclinical , Epithelial Cells/drug effects , Epithelial Cells/physiology , Mice , Oxazepines/chemistry , Oxazepines/toxicity , Trichuriasis/prevention & controlABSTRACT
Two novel series of oxazepine and diazepine based HSP90 inhibitors are reported. This effort relied on structure based design and isothermal calorimetry to identify small drug like macrocycles. Computational modelling was used to build into a solvent exposed pocket near the opening of the ATP binding site, which led to potent inhibitors of HSP90 (25-30).
Subject(s)
Amides/chemistry , Benzodiazepines/chemistry , HSP90 Heat-Shock Proteins/antagonists & inhibitors , Indoles/chemistry , Oxazepines/chemistry , Adenosine Triphosphate/chemistry , Adenosine Triphosphate/metabolism , Amides/metabolism , Amides/pharmacology , Animals , Azepines/chemistry , Benzamides/chemistry , Benzamides/metabolism , Benzodiazepines/metabolism , Benzodiazepines/pharmacology , Binding Sites , Cell Membrane Permeability/drug effects , Crystallography, X-Ray , Dogs , Drug Evaluation, Preclinical , HSP90 Heat-Shock Proteins/metabolism , Indoles/metabolism , Indoles/pharmacology , Madin Darby Canine Kidney Cells , Molecular Docking Simulation , Oxazepines/metabolism , Oxazepines/pharmacology , Protein Binding , Protein Structure, Tertiary , Structure-Activity Relationship , ortho-Aminobenzoates/chemistry , ortho-Aminobenzoates/metabolismABSTRACT
The progesterone receptor (PR), a member of nuclear receptor superfamily, is closely associated with gestational, type 1 and type 2 diabetes. However, the underlying mechanisms remain obscure. Here we found that PR activation increased the pro-inflammatory cytokines (PIC)-induced injury in Min6 cells, and PR blockage with siRNA interference protected the cells from damage. Moreover, the new discovered PR antagonist SC51089 effectively improved cell survival by reducing the PIC-stimulated cell apoptosis in Min6 cells. Immunoblotting assays indicated that either PR agonist progesterone (P4) or PR-B over-expression promoted the PIC-induced reinforces of extracellular-signal-regulated kinase 1/2 phosphorylation (p-Erk) and protein 53 (p53), and the attenuations of protein kinase B phosphorylation (p-AKT) and tumor necrosis factor receptor-associated factor 2 (TRAF2). SC51089 could reverse all the P4- or PR-B over-expression induced effects. In addition, PR siRNA inference based assay further supported that SC51089 protected pancreatic islet beta cells from the PR activation or PIC-induced injury by targeting PR and this protective action was mediated by AKT signaling pathway. To our knowledge, this current work might be the first report on the regulation of PR in pancreatic islet beta cell survival. It is expected that SC51089, as a non-steroid PR antagonist, might also find its potential in anti-diabetic research.
Subject(s)
Hydrazines/pharmacology , Hypoglycemic Agents/pharmacology , Insulin-Secreting Cells/physiology , Oxazepines/pharmacology , Receptors, Progesterone/metabolism , Animals , Apoptosis/drug effects , Cell Survival , Cytokines/pharmacology , Cytokines/physiology , Drug Evaluation, Preclinical , Gene Knockdown Techniques , HEK293 Cells , Humans , Inflammation Mediators/pharmacology , Inflammation Mediators/physiology , MCF-7 Cells , Mice , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Progesterone/antagonists & inhibitors , Receptors, Progesterone/genetics , Transcription, GeneticABSTRACT
Alterations in fat metabolism, in particular elevated plasma concentrations of free fatty acids and triglycerides (TG), have been implicated in the pathogenesis of Type 2 diabetes, obesity, and cardiovascular disease. Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), a member of the large family of membrane-bound O-acyltransferases, catalyzes the final step in triacylglycerol formation. In the intestine, DGAT1 is one of the acyltransferases responsible for the reesterficiation of dietary TG. Following a single dose of a selective pharmacological inhibitor of DGAT1, PF-04620110, a dose-dependent inhibition of TG and vitamin A absorption postprandially was demonstrated in rodents and human subjects. In C57/BL6J mice, acute DGAT1 inhibition alters the temporal and spatial pattern of dietary lipid absorption. To understand the impact of DGAT1 inhibition on enterocyte lipid metabolism, lipomic profiling was performed in rat intestine and plasma as well as human plasma. DGAT1 inhibition causes an enrichment of polyunsaturated fatty acids within the TG class of lipids. This pharmacological intervention gives us insight as to the role of DGAT1 in human dietary lipid absorption.
Subject(s)
Diacylglycerol O-Acyltransferase/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Intestinal Absorption/drug effects , Oxazepines/pharmacology , Adolescent , Adult , Animals , Case-Control Studies , Diacylglycerol O-Acyltransferase/genetics , Diacylglycerol O-Acyltransferase/metabolism , Dietary Fats/blood , Dietary Fats/metabolism , Dose-Response Relationship, Drug , Enterocytes/metabolism , Enzyme Inhibitors/pharmacokinetics , Fatty Acids, Unsaturated/blood , Fatty Acids, Unsaturated/metabolism , Female , Humans , Intestinal Mucosa/metabolism , Lipid Metabolism/drug effects , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Middle Aged , Oxazepines/pharmacokinetics , Postprandial Period , Rats , Rats, Sprague-Dawley , Triglycerides/blood , Triglycerides/metabolism , Vitamin A/metabolismABSTRACT
Multiple lines of evidence indicate that regional brain eicosanoid signaling is important in initiation and progression of neurodegenerative conditions that have neuroinflammatory pathologic component, such as AD. We hypothesized that PGE(2) receptor subtype 1 (EP1) signaling (linked to intracellular Ca(2+) release) regulates Aß peptide neurotoxicity and tested this in two complementary in vitro models: a human neuroblastoma cell line (MC65) producing Aß(1-40) through conditional expression of the APP C-terminal portion, and murine primary cortical neuron cultures exposed to Aß(1-42). In MC65 cells, EP1 receptor antagonist SC-51089 reduced Aß neurotoxicity ~50 % without altering high molecular weight Aß immunoreactive species formation. Inositol-3-phosphate receptor antagonist 2-aminoethoxy-diphenyl borate offered similar protection. SC-51089 largely protected the neuron cultures from synthetic Aß(1-42) neurotoxicity. Nimodipine, a Ca(2+) channel blocker, was completely neuroprotective in both models. Based on these data, we conclude that suppressing neuronal EP1 signaling may represent a promising therapeutic approach to ameliorate Aß peptide neurotoxicity.
Subject(s)
Amyloid beta-Peptides/antagonists & inhibitors , Amyloid beta-Peptides/toxicity , Dinoprostone/metabolism , Neurotoxicity Syndromes/prevention & control , Prostaglandin Antagonists/pharmacology , Receptors, Prostaglandin E, EP1 Subtype/drug effects , Animals , Blotting, Western , Calcium Channel Blockers/pharmacology , Cell Line, Tumor , Cells, Cultured , Coloring Agents , Humans , Hydrazines/pharmacology , Mice , Mice, Inbred C57BL , Neurons/drug effects , Neurotoxicity Syndromes/pathology , Nimodipine/pharmacology , Oxazepines/pharmacology , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/toxicity , Tetrazolium Salts , ThiazolesABSTRACT
Advanced hormone-refractory prostate cancer is associated with poor prognosis and limited treatment options. Members of the pyrrolo-1,5-benzoxazepine (PBOX) family of compounds exhibit anti-cancer properties in cancer cell lines (including multi-drug resistant cells), ex vivo patient samples and in vivo mouse tumour models with minimal toxicity to normal cells. Recently, they have also been found to possess anti-angiogenic properties in vitro. However, both the apoptotic pathways and the overall extent of the apoptotic response induced by PBOX compounds tend to be cell-type specific. Since the effect of the PBOX compounds on prostate cancer has not yet been elucidated, the purpose of this study was to investigate if PBOX compounds induce anti-proliferative effects on hormone-refractory prostate cancer cells. We examined the effect of two representative PBOX compounds, PBOX-6 and PBOX-15, on the androgen-independent human prostate adenocarcinoma cell line, PC3. PBOX-6 and -15 displayed anti-proliferative effects on PC3 cells, mediated initially through a sustained G2/M arrest. G2/M arrest, illustrated as DNA tetraploidy, was accompanied by microtubule depolymerisation and phosphorylation of anti-apoptotic proteins Bcl-2 and Bcl-xL and the mitotic spindle checkpoint protein BubR1. Phosphorylation of BubR1 is indicative of an active mitotic checkpoint and results in maintenance of cell cycle arrest. G2/M arrest was followed by apoptosis illustrated by DNA hypoploidy and PARP cleavage and was accompanied by degradation of BubR1, Bcl-2 and Bcl-xL. Furthermore, sequential treatment with the CDK1-inhibitor, flavopiridol, synergistically enhanced PBOX-induced apoptosis. In summary, this in vitro study indicates that PBOX compounds may be useful alone or in combination with other agents in the treatment of hormone-refractory prostate cancer.
Subject(s)
Adenocarcinoma/pathology , Apoptosis/drug effects , Cell Cycle/drug effects , Oxazepines/pharmacology , Prostatic Neoplasms/pathology , Tubulin Modulators/pharmacology , Antineoplastic Agents/pharmacology , Apoptosis/physiology , Cell Cycle/physiology , Cell Line, Tumor , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Humans , Inhibitory Concentration 50 , Male , Models, Biological , Pyrroles/pharmacologyABSTRACT
In trials to preserve the pharmacological profile and improve the bioavailability via lipophilicity increment of baclofen 1 and searching for more potent and less toxic muscle relaxants and analgesics, nine substituted cyclic analogues of 1 were designed and synthesized. The target derivatives 5-(4-chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one (11-19) were obtained through amide formation to the corresponding intermediates (2-10) followed by cyclization using acetic anhydride. The structures of the target compounds (11-19) were confirmed by IR, (1)H NMR, MS, and elemental analyses. The neuropharmacological activities of these lipophilic cyclic analogues (11-19) were assessed for their effects on motor activity, muscle relaxation, pain relief and impaired cognition, by intraperitoneal administration at a dose of 3mg/kg with reference to those of baclofen 1. Our results showed that compounds 11-14 are devoid of all of the tested pharmacological effects associated with 1. In all paradigms tested, undecyl, tridecyl, heptdec-8-enyl and benzyl substituted analogue derivatives (15, 16, 18, and 19) revealed a significant neurological activity being vividly favorable comparable with baclofen 1. 2-Benzyl-5-(4-chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivative 19 is the most active candidate with high significant neurological potencies, while 5-(4-chlorophenyl)-2-(dec-8-enyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivative 17 displayed activity at relatively higher time interval. These results probe a new structurally distinct class incorporating 1,3-oxazepine nucleus as promising candidates as GABA(B) agonists for further investigations.
Subject(s)
Baclofen/chemistry , Cognition Disorders/drug therapy , Drug Design , Muscle Relaxation/drug effects , Oxazepines/chemical synthesis , Oxazepines/pharmacology , Pain/drug therapy , Animals , Baclofen/pharmacology , Cyclization , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , GABA Agonists/chemical synthesis , GABA Agonists/chemistry , GABA Agonists/pharmacology , GABA-B Receptor Agonists , Hydrophobic and Hydrophilic Interactions , Injections, Intraperitoneal , Magnetic Resonance Spectroscopy/methods , Magnetic Resonance Spectroscopy/standards , Male , Mice , Molecular Structure , Motor Activity/drug effects , Oxazepines/chemistry , Receptors, GABA-B/chemistry , Reference Standards , StereoisomerismABSTRACT
BACKGROUND AND PURPOSE: Inhibition of squalene synthesis could transform unstable, macrophage/lipid-rich coronary plaques into stable, fibromuscular plaques. We have here treated WHHLMI rabbits, a model for coronary atherosclerosis and myocardial infarction, with a novel squalene synthase inhibitor, lapaquistat acetate (TAK-475). EXPERIMENTAL APPROACH: Young male WHHLMI rabbits were fed a diet supplemented with lapaquistat acetate (100 or 200 mg per kg body weight per day) for 32 weeks. Serum lipid levels were monitored every 4 weeks. After the treatment, lipoprotein lipid and coenzyme Q10 levels were assayed, and coronary atherosclerosis and xanthomas were examined histopathologically or immunohistochemically. From histopathological and immunohistochemical sections, the composition of the plaque was analysed quantitatively with computer-assisted image analysis. Xanthoma was evaluated grossly. KEY RESULTS: Lapaquistat acetate decreased plasma cholesterol and triglyceride levels, by lowering lipoproteins containing apoB100. Development of atherosclerosis and xanthomatosis was suppressed. Accumulation of oxidized lipoproteins, macrophages and extracellular lipid was decreased in coronary plaques of treated animals. Treatment with lapaquistat acetate increased collagen concentration and transformed coronary plaques into fibromuscular plaques. Lapaquistat acetate also suppressed the expression of matrix metalloproteinase-1 and plasminogen activator inhibitor-1 in the plaque and increased peripheral coenzyme Q10 levels. Increased coenzyme Q10 levels and decreased very low-density lipoprotein cholesterol levels were correlated with improvement of coronary plaque composition. CONCLUSION AND IMPLICATIONS: Inhibition of squalene synthase by lapaquistat acetate delayed progression of coronary atherosclerosis and changed coronary atheromatous plaques from unstable, macrophage/lipid accumulation-rich, lesions to stable fibromuscular lesions.
Subject(s)
Coronary Artery Disease/prevention & control , Enzyme Inhibitors/pharmacology , Farnesyl-Diphosphate Farnesyltransferase/antagonists & inhibitors , Hypercholesterolemia/drug therapy , Hypolipidemic Agents/pharmacology , Macrophages/drug effects , Oxazepines/pharmacology , Piperidines/pharmacology , Xanthomatosis/prevention & control , Animals , Apolipoprotein B-100/blood , Cholesterol/blood , Collagen/metabolism , Coronary Artery Disease/enzymology , Coronary Artery Disease/etiology , Coronary Artery Disease/pathology , Disease Models, Animal , Disease Progression , Dose-Response Relationship, Drug , Enzyme Inhibitors/blood , Farnesyl-Diphosphate Farnesyltransferase/metabolism , Hypercholesterolemia/complications , Hypercholesterolemia/enzymology , Hypercholesterolemia/pathology , Hypolipidemic Agents/blood , Image Interpretation, Computer-Assisted , Immunohistochemistry , Lipid Metabolism/drug effects , Lipoproteins, LDL/metabolism , Macrophages/pathology , Male , Matrix Metalloproteinase 1/metabolism , Oxazepines/blood , Piperidines/blood , Plasminogen Activator Inhibitor 1/metabolism , Rabbits , Triglycerides/blood , Ubiquinone/analogs & derivatives , Ubiquinone/metabolism , Xanthomatosis/enzymology , Xanthomatosis/etiology , Xanthomatosis/pathologyABSTRACT
Once-daily s.c. administration of either human parathyroid hormone (PTH)-(1-84) or recombinant human PTH-(1-34) provides for dramatic increases in bone mass in women with postmenopausal osteoporosis. We initiated a program to discover orally bioavailable small molecule equivalents of these peptides. A traditional high-throughput screening approach using cAMP activation of the PTH/PTH-related peptide receptor (PPR) as a readout failed to provide any lead compounds. Accordingly, we designed a new screen for this receptor that used a modified N-terminal fragment of PTH as a probe for small molecule binding to the transmembrane region of the PPR, driven by the assumption that the pharmacological properties (agonist/antagonist) of compounds that bound to this putative signaling domain of the PPR could be altered by chemical modification. We developed DPC-AJ1951, a 14 amino acid peptide that acts as a potent agonist of the PPR, and characterized its activity in ex vivo and in vivo assays of bone resorption. In addition, we studied its ability to initiate gene transcription by using microarray technology. Together, these experiments indicated that the highly modified 14 amino acid peptide induces qualitatively similar biological responses to those produced by PTH-(1-34), albeit with lower potency relative to the parent peptide. Encouraged by these data, we performed a screen of a small compound collection by using DPC-AJ1951 as the ligand. These studies led to the identification of the benzoxazepinone SW106, a previously unrecognized small molecule antagonist for the PPR. The binding of SW106 to the PPR was rationalized by using a homology receptor model.
Subject(s)
Molecular Probes/physiology , Oxazepines/pharmacology , Parathyroid Hormone/physiology , Peptide Fragments/physiology , Receptor, Parathyroid Hormone, Type 1/antagonists & inhibitors , Amino Acid Sequence , Animals , Binding, Competitive , Cell Line , Drug Evaluation, Preclinical , Humans , Male , Molecular Probe Techniques , Molecular Sequence Data , Oxazepines/agonists , Parathyroid Hormone/agonists , Parathyroid Hormone/metabolism , Peptide Fragments/agonists , Peptide Fragments/metabolism , Protein Binding , Rats , Rats, Sprague-Dawley , Receptor, Parathyroid Hormone, Type 1/agonists , Receptor, Parathyroid Hormone, Type 1/metabolismABSTRACT
A new series of 1,4-benzoxazepine derivatives was designed, synthesized, and evaluated for binding to 5-HT1A receptor and cerebral anti-ischemic effect. A lot of compounds exhibited nanomolar affinity for 5-HT1A receptor with good selectivity over both dopamine D2 and alpha1-adrenergic receptors. Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model.
Subject(s)
Ischemic Attack, Transient/drug therapy , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Oxazepines/chemistry , Serotonin 5-HT1 Receptor Agonists , Serotonin Receptor Agonists/chemistry , Animals , Brain/blood supply , Brain/drug effects , Brain/pathology , Disease Models, Animal , Drug Evaluation, Preclinical , Male , Models, Molecular , Molecular Structure , Neuroprotective Agents/chemistry , Oxazepines/chemical synthesis , Oxazepines/pharmacology , Rats , Rats, Wistar , Serotonin Receptor Agonists/chemical synthesis , Serotonin Receptor Agonists/pharmacology , Structure-Activity RelationshipABSTRACT
The extensive pharmacological evaluation of JL 13 as an atypical antipsychotic drug has revealed a close similarity to clozapine, however with some major advantages. JL 13 was characterized as a weak D(2) antagonist, both in vitro and in vivo, with a strong affinity for the D(4) and the 5-HT(2A) receptors. It has no affinity for the 5-HT(2C) receptor. In vivo microdialysis experiments in rat showed that JL 13, like clozapine, preferentially increased extracellular dopamine concentrations in the prefrontal cortex compared to nucleus accumbens or striatum. Behavioral studies showed that JL 13, like clozapine, has the profile of an atypical antipsychotic. Thus, JL 13 did not antagonize apomorphine-induced stereotypy nor did it produce catalepsy, but it antagonized apomorphine-induced climbing in rodents. It was inactive against d-amphetamine-induced stereotypy but antagonized d-amphetamine-induced hyperactivity in the mouse. Likewise, in the paw test, it was more effective in prolonging hindlimb retraction time than prolonging forelimb retraction time. Like other antipsychotic drugs, JL 13 reversed the apomorphine- and amphetamine-induced disruption of prepulse inhibition. In a complex temporal regulation schedule in the dog, JL 13 showed a high resemblance with clozapine without inducing sialorrhea, palpebral ptosis or any significant motor side effects. In rats and squirrel monkeys JL 13 induced a high degree of generalization (70%) to clozapine. Regarding behavioral toxicology, JL 13 did not produce dystonia or Parkinsonian symptoms in haloperidol-sensitized monkeys. After acute administration, again like clozapine, JL 13 induced only a transient increase in circulating prolactin. Last but not the least, regarding a possible hematological toxicity, unlike clozapine, JL 13 did not present sensitivity to peroxidase-induced oxidation. Moreover, its electrooxidation potential was close to that of loxapine and far from that of clozapine. Taking all these preclinical data into account, it appears that JL 13 is a promising atypical antipsychotic drug.
Subject(s)
Antipsychotic Agents/pharmacology , Dopamine Antagonists/pharmacology , Oxazepines/pharmacology , Piperazines/pharmacology , Pyridines/pharmacology , Animals , Antipsychotic Agents/adverse effects , Antipsychotic Agents/pharmacokinetics , Brain/drug effects , Cebidae , Clozapine/analogs & derivatives , Clozapine/pharmacology , Discrimination Learning/drug effects , Discrimination, Psychological/drug effects , Dopamine Antagonists/adverse effects , Dopamine Antagonists/pharmacokinetics , Drug Evaluation, Preclinical , Hematologic Diseases/chemically induced , Hyperprolactinemia/chemically induced , Mice , Oxazepines/adverse effects , Oxazepines/pharmacokinetics , Piperazines/adverse effects , Piperazines/pharmacokinetics , Psychotropic Drugs/pharmacology , Pyridines/adverse effects , Pyridines/pharmacokinetics , Rats , Saimiri , Tissue DistributionABSTRACT
A variety of fused heterocyclic compounds (2-11) were synthesized as a modification of the lead compound 1a and evaluated for their inhibition of squalene synthase. 4,1-Benzothiazepine derivative 2, 1,4-benzodiazepine derivative 6, 1,3-benzodiazepine derivative 7, 1-benzazepine derivative 9, and 4,1-benzoxazocine derivative 10 potently inhibited squalene synthase activity, whereas the 4,1-benzoxazepine derivatives 1 was the most potent inhibitor. 4,1-Benzothiazepine S-oxide derivative 4, 1,4-benzodiazepine derivative 5, 1,3,4-benzotriazepine derivative 8, and 1,2,3,4-tetrahydroquinoline derivative 11 were found to be weakly active. Comparison of the X-ray structures of these compounds (1a, 2, 4, 5, 7 and 10) suggests that orientation of the 5- (or 6)-phenyl group is important for activity.
Subject(s)
Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Farnesyl-Diphosphate Farnesyltransferase/antagonists & inhibitors , Heterocyclic Compounds/chemical synthesis , Oxazepines/chemistry , Oxazepines/pharmacology , Animals , Crystallography, X-Ray , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemical synthesis , Heterocyclic Compounds/pharmacology , Humans , Inhibitory Concentration 50 , Liver/enzymology , Male , Molecular Structure , Rats , Rats, Inbred Strains , Structure-Activity RelationshipABSTRACT
A series of (3,5-trans)-2-oxo-5-phenyl-1,2,3,5-tetrahydro-4,1-benzoxazepine derivatives were synthesized and evaluated for squalene synthase inhibitory and cholesterol biosynthesis inhibitory activities. Through modification of substituents of the lead compounds 1a and 1b, it was found that 4,1-benzoxazepine-3-acetic acid derivatives with isobutyl and neopentyl groups at the 1-position, the chloro atom at the 7-position, and the chloro and methoxy groups at the 2'-position on the 5-phenyl ring, had potent squalene synthase inhibitory activity. Among such compounds, the 5-(2,3-dimethoxyphenyl) derivative 2t exhibited potent inhibition of cholesterol biosynthesis in HepG2 cells. As a result of optical resolution study of 2t, the absolute stereochemistry required for inhibitory activity was determined to be 3R,5S. In vivo study showed that the sodium salt of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid 20 effectively reduced plasma cholesterol in marmosets.
Subject(s)
Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Farnesyl-Diphosphate Farnesyltransferase/antagonists & inhibitors , Oxazepines/chemistry , Oxazepines/pharmacology , Administration, Oral , Animals , Callithrix , Carcinoma, Hepatocellular/enzymology , Cholesterol/blood , Drug Evaluation, Preclinical , Humans , Inhibitory Concentration 50 , Liver/enzymology , Male , Rats , Rats, Wistar , Structure-Activity Relationship , Tumor Cells, CulturedABSTRACT
Oxapadol is a non-narcotic analgesic with an unusual chemical structure. It possesses analgesic activity in 4 species similar to that of other non-narcotic reference analgesics. It also shows antipyretic and antiinflammatory effects and in the analgesic dose range is devoid of undesirable neurological, gastro-intestinal and cardiovascular side-effects.